Lab News

New paper published on cutaneous neurofibroma organoids

May 14, 2024
We have a new paper published today in Cell Reports Methods reporting on our mini-ring platform for benign tumor screening. Congratulations to Huyen on her first author paper, the second for her from the lab! Click below to read a short summary of the work.

Soragni Lab at AACR24

April 6, 2024
The Soragni Lab will be present in force at the 2024 Annual AACR Meeting in San Diego! Luda will present a poster on our chemoradiation platform for head and neck cancer organoids on Sunday. On Monday, Alice will chair a session on organoids and talk about heterogeneity and genetic diversity in patient-derived organoids from rare benign and malignant tumors while Sara will be presenting a poster on protein aggregation in ovarian cancer.

Chords2Cure fundraising to support pediatric sarcoma research in the Soragni Lab

March 31, 2024
The lab is very grateful to the C2C team which is spearheaded by a group of fantastic teen advocates! Their tireless efforts in raising funds to support our lab research on pediatric sarcomas have so far allowed us to test more patient samples, quickly and robustly.

AACR-Margaret Foti Foundation Scholar-in-Training Award

February 27, 2024
Huge congratulations to Sara who won the AACR-Margaret Foti Foundation Scholar-in-Training Award to attend the 2024 AACR Annual Meeting in San Diego! Dr. Sartini will present her work on p53 aggregation in ovarian cancer on April 8, 2024 from 1:30 PM to 5:00 PM in session PO.MCB11.01 (Poster 3027/25).

PREMOST organoid-based trial open for enrollment

February 1, 2024
Our very first clinical trial that leverages patient-derived tumor organoids in osteosarcoma is officially open and enrolling! PREMOST, An Organoid-based Functional Precision Medicine Trial in Osteosarcoma (NCT06064682) is open to patients of any age with either a suspect osteosarcoma diagnosis (Arm 1) or recurrent/metastatic osteosarcoma (Arm 2). We will test feasibility to develop organoids from these cases and determine the prognostic power of the assay as well as return results to the clinic through our sarcoma tumor board.